OBJECTIVES: This phase 1 study investigated safety/tolerability, pharmacokinetics, and preliminary efficacy of SC-002, a delta-like ligand 3-directed antibody-drug conjugate, in advanced small cell lung cancer and large cell neuroendocrine carcinoma. MATERIALS AND METHODS: Eligible patients received SC-002 at 1 of 7 dose levels during the dose-escalation portion of the study. RESULTS: Thirty-five enrolled patients received ≥1 dose of SC-002. Twenty-three (66%) patients experienced serious adverse events (AEs), 37% considered related to SC-002. Grade 3/4 AEs occurred in 21 (60%) and 2 (6%) patients; the most common were effusion and hypoalbuminemia. One grade 5 AE occurred in 1 patient. Five (14%) patients achieved a partial response and no patients achieved a complete response. CONCLUSION: SC-002 treatment was associated with systemic toxicity and limited efficacy.
OBJECTIVES: This phase 1 study investigated safety/tolerability, pharmacokinetics, and preliminary efficacy of SC-002, a delta-like ligand 3-directed antibody-drug conjugate, in advanced small cell lung cancer and large cell neuroendocrine carcinoma. MATERIALS AND METHODS: Eligible patients received SC-002 at 1 of 7 dose levels during the dose-escalation portion of the study. RESULTS: Thirty-five enrolled patients received ≥1 dose of SC-002. Twenty-three (66%) patients experienced serious adverse events (AEs), 37% considered related to SC-002. Grade 3/4 AEs occurred in 21 (60%) and 2 (6%) patients; the most common were effusion and hypoalbuminemia. One grade 5 AE occurred in 1 patient. Five (14%) patients achieved a partial response and no patients achieved a complete response. CONCLUSION:SC-002 treatment was associated with systemic toxicity and limited efficacy.
Authors: Laura R Saunders; Alexander J Bankovich; Wade C Anderson; Monette A Aujay; Sheila Bheddah; KristenAnn Black; Radhika Desai; Paul A Escarpe; Johannes Hampl; Amy Laysang; David Liu; Javier Lopez-Molina; Milly Milton; Albert Park; Marybeth A Pysz; Hui Shao; Brian Slingerland; Michael Torgov; Samuel A Williams; Orit Foord; Philip Howard; Jacek Jassem; Andrzej Badzio; Piotr Czapiewski; David H Harpole; Afshin Dowlati; Pierre P Massion; William D Travis; M Catherine Pietanza; J T Poirier; Charles M Rudin; Robert A Stull; Scott J Dylla Journal: Sci Transl Med Date: 2015-08-26 Impact factor: 17.956
Authors: Vadim S Koshkin; Jorge A Garcia; Jordan Reynolds; Paul Elson; Cristina Magi-Galluzzi; Jesse K McKenney; Kumiko Isse; Evan Bishop; Laura R Saunders; Aysegul Balyimez; Summya Rashid; Ming Hu; Andrew J Stephenson; Amr F Fergany; Byron H Lee; Georges-Pascal Haber; Afshin Dowlati; Timothy Gilligan; Moshe C Ornstein; Brian I Rini; Mohamed E Abazeed; Omar Y Mian; Petros Grivas Journal: Clin Cancer Res Date: 2018-10-16 Impact factor: 12.531
Authors: Charles M Rudin; M Catherine Pietanza; Todd M Bauer; Neal Ready; Daniel Morgensztern; Bonnie S Glisson; Lauren A Byers; Melissa L Johnson; Howard A Burris; Francisco Robert; Tae H Han; Sheila Bheddah; Noah Theiss; Sky Watson; Deepan Mathur; Bharathi Vennapusa; Hany Zayed; Satwant Lally; Donald K Strickland; Ramaswamy Govindan; Scott J Dylla; Stanford L Peng; David R Spigel Journal: Lancet Oncol Date: 2016-12-05 Impact factor: 41.316
Authors: Daniel Morgensztern; Benjamin Besse; Laurent Greillier; Rafael Santana-Davila; Neal Ready; Christine L Hann; Bonnie S Glisson; Anna F Farago; Afshin Dowlati; Charles M Rudin; Sylvestre Le Moulec; Satwant Lally; Sreeni Yalamanchili; Jürgen Wolf; Ramaswamy Govindan; David P Carbone Journal: Clin Cancer Res Date: 2019-09-10 Impact factor: 12.531
Authors: Dwight H Owen; Michael J Giffin; Julie M Bailis; Marie-Anne Damiette Smit; David P Carbone; Kai He Journal: J Hematol Oncol Date: 2019-06-18 Impact factor: 17.388